Search Results

Innate Pharma SA announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation.

Innate Pharma SA announced the voting results of its shareholders at the Annual General Meeting, which took place on May 23, 2024, in Marseille.

Innate Pharma SA announced that updated efficacy and safety results from the dose-escalation part of the Phase 1/2 study with SAR443579/IPH6101 from a joint research collaboration between Innate Pharma and Sanofi and ANKET® platform lead asset, were shared in an oral presentation at the European Hematology Association 2024 Congress in Madrid, Spain on Sunday, June 16 at 11:45 CEST.

Regulatory News: Innate Pharma SA announced members of its executive team are scheduled to participate in the upcoming conferences, detailed below.

Innate Pharma SA announced favorable results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides.

Innate Pharma SA reported its consolidated financial results for the quarter ending March 31, 2024.

Celon Pharma S.A. (CLN.WA) today announced the successful completion of a Phase 2 trial a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA).

Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.

Innate Pharma SA announced that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.